scholarly journals EFFICACY OF SOFOSBUVIR PLUS VALPATASVIR BASED THERAPY IN THE TREATMENT OF TREATMENT NAIVE CHRONIC HEPATITIS C GENOTYPE-3 IN KASHMIR.

2020 ◽  
Vol 4 (4) ◽  
Author(s):  
Shabir Shiekh ◽  
Shafat Lone ◽  
Zafar Wani ◽  
Zafar Kawoosa ◽  
Showkat A. Kadla
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Fixed Dose ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Treatment Naïve ◽  
Direct Acting

Abstracts Objectives: Direct acting antivirals (DAAs) have dramatically changed our approach towards management of chronic hepatitis C by yielding a high sustained virological response (SVR). Genotype-3 is the most common genotype found in Kashmir (Northern India) besides having an aggressive nature with increased risk of steatosis and hepatocellular carcinoma. We assessed the efficacy and safety of sofosbuvir plus valpatasvir based therapy in chronic hepatitis C genotype-3 infection in Kashmiri population. Aims and objectives: An observational, prospective, open label, hospital based study was carried over a period of two years which included 230 treatment naïve chronic hepatitis-C genotype-3 patients. Patients were divided in two groups. Group-A: Non-cirrhotics who received sofosbuvir (400 mg daily) with valpatasvir (100 mg) in fixed–dose combination for 12 weeks. Group B included CPT class A cirrhotics who received sofosbuvir (400mg daily) with valpatasvir (100 mg daily) and weight based ribavarin for 12 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. Results and observations: We observed 98.57 % (138/140) SVR 12 in non-cirrhotics who received valpatasvir plus sofosbuvir treatment regimen. Cirrhotics who received Sofosbuvir plus valpatasvir with ribavirin observed SVR of 96.6 % (87/90). All patients tolerated the drug regimens well without any serious adverse effect. Conclusion: Once daily oral Sofosbuvir plus valpatasvir based fixed dose rerimen is highly efficient and safe in treatment of both cirrhotics and non-cirrhotic hepatitis C patients. Keywords: Direct acting antivirals; sustained virological response; Genotype; chronic hepatitis C

EFFICACY OF SOFOSBUVIR AND DACLATASVIR IN COMPENSATED CHRONIC HEPATITIS C INFECTION: A SINGLE CENTER, OPEN-LABEL AND PROOF OF CONCEPT STUDY

2021 ◽  
pp. 27-30
Author(s):  
Manisha Thakur ◽  
Anurag Chauhan ◽  
Prashant Jambunathan ◽  
Shikha Awasthi ◽  
Thilagavathi K ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Sustained Viral Response ◽  
Hcv Rna ◽  
Hepatitis C Infection ◽  
Genotype 3 ◽  
Treatment Naïve

AIMS AND OBJECTIVES: The advent of directly acting agents for the treatment of Hepatitis C infection has forever transformed our understanding and management of viral infections. With over 95 % patients achieving a sustained viral response at 12 weeks with some of these newly inducted agents, the prospect of eradicating the Hepatitis C virus seems like an achievable target, which makes this one of the most important discoveries in modern medicine. We studied the combination of Sofosbuvir and Daclatasvir in patients with chronic hepatitis C infection (Genotype 3) to assess the rates of sustained virological response at 12 weeks. We studied 67 treatment naive METHODS: patients with compensated chronic hepatitis C infection (genotype 3). They were all started on Tab Sofosbuvir 400 mg daily and Tab Daclatasvir 60 mg once daily for 12 weeks and followed up for a total of 24 weeks, which includes a treatment duration and observation period of 12 weeks each. The patients were monitored with HCV RNA levels at one, three and six months, with as many evaluations of liver function and routine hemogram. Our results show that 70.5% (p<0.05) achieved a rapid vi RESULTS: rological response, 88.5% (p<0.05) achieved an end of treatment response and, similarly, an impressive 88.05% (p<0.05) showed a sustained virological response at the end of 12 weeks. One patient who developed a psoriasiform rash discontinued the medication and was excluded from the analysis, as duration of treatment had not been completed. No major dose related adverse events were reported. Sofosbuvir and Daclatasvir is an acceptable, well tolerated regimen for treatment naive, CONCLUSIONS: compensated patients with genotype 3 infection. Based on our observations and data, we recommend this as the rst line DAA for patient with compensated genotype 3 infection until medications with higher SVR 12 are available in the Indian market.

scholarly journals The impact of achieving a sustained virological response with direct-acting antivirals on serum autotaxin levels in chronic hepatitis C patients

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Shereen Abou Bakr Saleh ◽  
Khaled Mohamed Abdelwahab ◽  
Asmaa Mady Mady ◽  
Ghada Abdelrahman Mohamed
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Hepatic Fibrosis ◽  
Virological Response ◽  
Direct Acting Antivirals ◽  
Fibrosis Regression ◽  
Direct Acting ◽  
The Impact

Abstract Background Autotaxin (ATX) is an emerging biomarker for liver fibrosis. Achievement of sustained virological response (SVR) by direct-acting antivirals (DAAs) results in hepatic fibrosis regression in chronic hepatitis C (CHC) patients. In this context, the clinical implications of ATX have not yet been well-defined. In this study, we aimed to assess the impact of achieving SVR with DAA therapy on serum ATX levels and whether these levels can reflect the regression of hepatic fibrosis in CHC patients. We evaluated serum ATX levels at baseline and 12 weeks post-DAA therapy in 48 CHC patients. We compared ATX with FIB4 score and AST-to-Platelet Ratio Index (APRI) as regards the detection of grade F3–4 fibrosis. Results Serum ATX levels were significantly declined in 47 patients after the achievement of SVR12 (p < 0.001). The diagnostic ability of ATX for the detection of grade F3–4 fibrosis was inferior to FIB4 and APRI scores at baseline and SVR12. Conclusion Achievement of SVR with DAA therapy causes a significant decline in serum autotaxin concentrations, suggesting early regression of hepatic fibrosis in CHC patients. However, its diagnostic capability for routine patient monitoring and follow-up is still under debate.

Sign in / Sign up

Export Citation Format

Share Document